Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(40%)
Terminated
1(20%)

Phase Distribution

Ph phase_2
5
100%

Phase Distribution

0

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
5(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Terminated(1)
Other(1)

Detailed Status

Not yet recruiting1
Recruiting1
Active, not recruiting1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 25 (100.0%)

Trials by Status

not_yet_recruiting120%
recruiting120%
active_not_recruiting120%
terminated120%
unknown120%

Recent Activity

2 active trials
Showing 5 of 5
active_not_recruitingphase_2

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT05481476
not_yet_recruitingphase_2

Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

NCT06916975
recruitingphase_2

Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

NCT06722911
unknownphase_2

Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis

NCT06405685
terminatedphase_2

PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer

NCT04176952

Clinical Trials (5)

Showing 5 of 5 trials
NCT05481476Phase 2

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Active Not Recruiting
NCT06916975Phase 2

Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Not Yet Recruiting
NCT06722911Phase 2

Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

Recruiting
NCT06405685Phase 2

Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis

Unknown
NCT04176952Phase 2

PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5